GB2571937B - Stable liquid suspension composition of fludrocortisone - Google Patents
Stable liquid suspension composition of fludrocortisone Download PDFInfo
- Publication number
- GB2571937B GB2571937B GB1803893.5A GB201803893A GB2571937B GB 2571937 B GB2571937 B GB 2571937B GB 201803893 A GB201803893 A GB 201803893A GB 2571937 B GB2571937 B GB 2571937B
- Authority
- GB
- United Kingdom
- Prior art keywords
- fludrocortisone
- liquid suspension
- stable liquid
- suspension composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical group O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 title 1
- 229960002011 fludrocortisone Drugs 0.000 title 1
- 239000006194 liquid suspension Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1803893.5A GB2571937B (en) | 2018-03-12 | 2018-03-12 | Stable liquid suspension composition of fludrocortisone |
| PCT/IB2019/051696 WO2019175703A1 (en) | 2018-03-12 | 2019-03-03 | Stable liquid suspension composition of fludrocortisone |
| EP19713218.6A EP3764989A1 (en) | 2018-03-12 | 2019-03-03 | Stable liquid suspension composition of fludrocortisone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1803893.5A GB2571937B (en) | 2018-03-12 | 2018-03-12 | Stable liquid suspension composition of fludrocortisone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB201803893D0 GB201803893D0 (en) | 2018-04-25 |
| GB2571937A GB2571937A (en) | 2019-09-18 |
| GB2571937B true GB2571937B (en) | 2021-07-14 |
Family
ID=61972944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB1803893.5A Expired - Fee Related GB2571937B (en) | 2018-03-12 | 2018-03-12 | Stable liquid suspension composition of fludrocortisone |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3764989A1 (en) |
| GB (1) | GB2571937B (en) |
| WO (1) | WO2019175703A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231000T1 (en) * | 2020-02-25 | 2023-12-08 | Labomed Pharmaceutical Company S.A. | ORAL SOLUTIONS CONTAINING FLUDROCORTISONE ACETATE |
| CN111759812A (en) * | 2020-07-20 | 2020-10-13 | 华益药业科技(安徽)有限公司 | Fludrocortisone acetate tablet for inhibiting proliferation of connective hoof tissue and processing technology thereof |
| CN111803457A (en) * | 2020-07-20 | 2020-10-23 | 华益药业科技(安徽)有限公司 | Fludrocortisone acetate tablet and processing technology thereof |
| CN111759814A (en) * | 2020-07-20 | 2020-10-13 | 华益药业科技(安徽)有限公司 | Fludrocortisone acetate tablet for resisting inflammation and processing technology |
| CN113350297B (en) * | 2021-06-11 | 2022-11-04 | 河南金大众生物工程有限公司 | Tilmicosin dry suspension and preparation method thereof |
| EP4376808A1 (en) * | 2021-07-30 | 2024-06-05 | Epygenix Therapeutics, Inc. | Clemizole formulation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
| WO2003082243A1 (en) * | 2002-04-03 | 2003-10-09 | Venus Danilo R | Oral suspension formulation |
| US20060093631A1 (en) * | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060013858A1 (en) * | 2002-10-29 | 2006-01-19 | Trune Dennis R | Fludrocortisone treatment for hearing loss |
| WO2007062266A2 (en) * | 2005-11-28 | 2007-05-31 | Marinus Pharmaceuticals | Ganaxolone formulations and methods for the making and use thereof |
| CA2669815A1 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| WO2010068775A2 (en) * | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| EP3110427A4 (en) * | 2014-02-24 | 2018-05-30 | Urigen Pharmaceuticals, Inc. | Compositions of pentosan polysulfate salts for oral administration and methods of use |
| EP3471725B1 (en) * | 2016-06-16 | 2025-02-19 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
-
2018
- 2018-03-12 GB GB1803893.5A patent/GB2571937B/en not_active Expired - Fee Related
-
2019
- 2019-03-03 EP EP19713218.6A patent/EP3764989A1/en not_active Withdrawn
- 2019-03-03 WO PCT/IB2019/051696 patent/WO2019175703A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
| WO2003082243A1 (en) * | 2002-04-03 | 2003-10-09 | Venus Danilo R | Oral suspension formulation |
| US20060093631A1 (en) * | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
Non-Patent Citations (1)
| Title |
|---|
| European Journal of Pharmaceutics and Biopharmaceutics, vol. 55, 2003, pages 209-213 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2571937A (en) | 2019-09-18 |
| WO2019175703A1 (en) | 2019-09-19 |
| GB201803893D0 (en) | 2018-04-25 |
| EP3764989A1 (en) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2571937B (en) | Stable liquid suspension composition of fludrocortisone | |
| ZA201800716B (en) | Heterocyclic compounds useful as modulators of tnf alpha | |
| ZA201802150B (en) | Compounds useful as modulators of trpm8 | |
| SG11202106378VA (en) | Modulators of hsd17b13 expression | |
| SG11202102636UA (en) | Modulators of pnpla3 expression | |
| ZA202007537B (en) | Modulators of apol1 expression | |
| GB2574740B (en) | Characterisation of emulsion stability | |
| IL285333A (en) | Modulators of malat1 expression | |
| IL273237B1 (en) | Novel heterocyclic compounds as modulators of mglur7 | |
| GB201913701D0 (en) | Composition of matter | |
| IL290324A (en) | Compositions of trofinetide | |
| GB201718468D0 (en) | Stable liquid pharmaceutical compositions of bortezomb | |
| PL3449931T3 (en) | Use of cerebrolysin | |
| IL270891B (en) | Formation of stable cartilage | |
| SG11202010971XA (en) | Small molecule modulators of mhc-i | |
| ZA202105399B (en) | Use of spiropidion | |
| GB201919180D0 (en) | New composition of matter | |
| PL3344242T3 (en) | Stable multiparticuate pharamaceutical composition of rosuvastatin | |
| SG11202105136WA (en) | Application of chidamide | |
| GB201910665D0 (en) | Novel form of compounds | |
| KR102388028B9 (en) | Composition for delivering of polypptide | |
| PT3901141T (en) | Novel form of isoquinolinesulfonamide | |
| ZA202201719B (en) | Stable polymorphic form of 6-fluoro-9-methyl-9h-beta-carboline and uses thereof | |
| GB201910666D0 (en) | Novel form of compounds | |
| GB201809911D0 (en) | Use of trpv1 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20220312 |